IL192773A0 - Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol - Google Patents

Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol

Info

Publication number
IL192773A0
IL192773A0 IL192773A IL19277308A IL192773A0 IL 192773 A0 IL192773 A0 IL 192773A0 IL 192773 A IL192773 A IL 192773A IL 19277308 A IL19277308 A IL 19277308A IL 192773 A0 IL192773 A0 IL 192773A0
Authority
IL
Israel
Prior art keywords
alcohol
active ingredient
immediate release
pharmaceutical forms
forms resistant
Prior art date
Application number
IL192773A
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of IL192773A0 publication Critical patent/IL192773A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL192773A 2006-02-16 2008-07-13 Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol IL192773A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0650566A FR2897267A1 (en) 2006-02-16 2006-02-16 MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION
PCT/EP2007/051528 WO2007093642A2 (en) 2006-02-16 2007-02-16 Microparticulate pharmaceutical forms resistant to immediate release of the active principle in the presence of alcohol

Publications (1)

Publication Number Publication Date
IL192773A0 true IL192773A0 (en) 2009-02-11

Family

ID=37103249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192773A IL192773A0 (en) 2006-02-16 2008-07-13 Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol

Country Status (13)

Country Link
EP (1) EP1986616B1 (en)
JP (1) JP5416974B2 (en)
KR (1) KR20080099270A (en)
CN (1) CN101378736B (en)
AU (1) AU2007216485A1 (en)
BR (1) BRPI0707859A2 (en)
CA (1) CA2649265C (en)
ES (1) ES2692450T3 (en)
FR (1) FR2897267A1 (en)
IL (1) IL192773A0 (en)
MX (1) MX2008010492A (en)
WO (1) WO2007093642A2 (en)
ZA (1) ZA200806118B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009968A (en) 2002-04-09 2004-12-13 Flamel Tech Sa Oral suspension of active principle microcapsules.
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2936709B1 (en) * 2008-10-02 2012-05-11 Ethypharm Sa ALCOHOL-RESISTANT TABLETS.
KR101264961B1 (en) 2008-11-07 2013-05-16 주식회사 삼양바이오팜 Release controlled pharmaceutical compositions of methylphenidate
WO2010057869A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
PL2358360T3 (en) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
PL2456424T3 (en) 2009-07-22 2013-12-31 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
WO2011051324A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Radiolabelled pde10 ligands
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2628303T3 (en) * 2011-06-01 2017-08-02 Fmc Corporation Solid dose controlled release forms
PE20141638A1 (en) 2011-07-29 2014-11-22 Gruenenthal Chemie HANDLE PROOF TABLET PROVIDING IMMEDIATE DRUG RELEASE
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CN102512415B (en) * 2011-12-16 2013-07-31 山东齐都药业有限公司 Clopidogrel bisulfate medicine composition and preparation method
EA201401139A1 (en) 2012-04-18 2015-03-31 Грюненталь Гмбх SUSTAINABLE TO DESTRUCTION AND DOSE RELEASE PHARMACEUTICAL DRUG FORM
JP5960523B2 (en) * 2012-06-29 2016-08-02 旭化成株式会社 Solid formulation consisting of modified starch and dissolution control agent
JP6449871B2 (en) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modified dosage form containing ethylene-vinyl acetate polymer
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6480936B2 (en) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Preparation of powdered pharmaceutical composition by cryomilling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) * 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
AU2015254875A1 (en) * 2014-05-01 2016-11-17 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
PL3137057T3 (en) * 2014-05-01 2021-04-06 Sun Pharmaceutical Industries Ltd Extended release liquid compositions of metformin
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
RU2017106010A (en) 2014-07-30 2018-08-28 Сан Фармасьютикал Индастриз Лимитед TWO CHAMBER PACKAGING
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
UY37341A (en) * 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2963929T3 (en) 2017-05-29 2024-04-03 Gruenenthal Gmbh Multiparticulate oral dosage form providing prolonged release of tapentadol
JP7110366B2 (en) * 2017-11-01 2022-08-01 エッジモント・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー・トラスト Alcohol-tolerant oral pharmaceutical composition of lorazepam
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113473980A (en) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state
GR1009751B (en) 2019-03-22 2020-05-29 "Φαρματεν Α.Β.Ε.Ε." Prolonged-release oxalic tapentadol -containing formula and preparation method thereof
GR1009791B (en) 2019-03-26 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Prolonged release tapentadol-containing formula - preparation method thereof
CN114340614B (en) * 2019-09-27 2024-01-16 广东东阳光药业股份有限公司 Oseltamivir preparation
CN112137990A (en) * 2020-11-04 2020-12-29 南京康川济医药科技有限公司 Epalrestat sustained-release preparation and preparation method thereof
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784390A (en) * 1971-07-23 1974-01-08 Hayashibara Biochem Lab Shaped bodies of pullulan and their use
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
ES2068762B1 (en) * 1993-07-21 1995-12-01 Lipotec Sa A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING.
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19809719A1 (en) * 1998-03-06 1999-09-09 Roehm Gmbh Aqueous dispersion for binder and coating for medicine
PL358909A1 (en) * 1998-04-27 2004-08-23 Janssen Pharmaceutica N.V. Pellets having a core coated with a lipid lowering agent and a polymer
JP3449253B2 (en) * 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 Manufacturing method of hard capsule
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SG126676A1 (en) * 2001-05-09 2007-01-30 Nanomaterials Tech Pte Ltd Process for the controlled production of organic particles
HUP0401191A3 (en) * 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
FR2850576B1 (en) * 2003-02-05 2007-03-23 Ethypharm Sa COMPOSITION COMPRISING A MIXTURE OF ACTIVE INGREDIENTS AND PROCESS FOR PREPARING THE SAME
ES2344294T3 (en) * 2003-05-02 2010-08-24 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. SOLID PHARMACEUTICAL PREPARATION CONTAINING SALTS OF LEVOTIROXIN AND / OR LIOTIRONINE.
EP1479383B1 (en) * 2003-05-20 2006-10-04 Ethypharm Oral sustained release pharmaceutical composition
WO2005011666A1 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Stable sustained release oral dosage form of gabapentin
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CA2557634A1 (en) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Stable capsule preparation
WO2005102287A2 (en) * 2004-04-22 2005-11-03 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
EP1814528A2 (en) * 2004-10-08 2007-08-08 Rubicon Research Private Limited Process for making a highly compressible controlled delivery compositions of metformin
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
GB0506982D0 (en) * 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
FR2892937B1 (en) * 2005-11-10 2013-04-05 Flamel Tech Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING

Also Published As

Publication number Publication date
MX2008010492A (en) 2009-02-04
FR2897267A1 (en) 2007-08-17
WO2007093642A2 (en) 2007-08-23
BRPI0707859A2 (en) 2011-05-10
CA2649265A1 (en) 2007-08-23
CN101378736B (en) 2015-08-19
EP1986616B1 (en) 2018-08-15
WO2007093642A3 (en) 2007-10-04
CA2649265C (en) 2019-01-29
EP1986616A2 (en) 2008-11-05
AU2007216485A1 (en) 2007-08-23
KR20080099270A (en) 2008-11-12
ZA200806118B (en) 2009-04-29
ES2692450T3 (en) 2018-12-03
JP2009526825A (en) 2009-07-23
CN101378736A (en) 2009-03-04
JP5416974B2 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
EP2130552A4 (en) Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
EP2078731A4 (en) Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
ZA200900345B (en) Preparation of pharmaceutical formulations
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
IL204528A (en) Combined sustained and immediate release metadoxine pharmaceutical dosage forms
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
HK1126667A1 (en) Self preserved aqueous pharmaceutical compositions
BRPI0908596A2 (en) prolonged release formulation and pharmaceutical composition
EP2379079A4 (en) Pharmaceutical formulations comprising voriconazole and processes for preparation thereof
EP2112925A4 (en) Solid pharmaceutical dosage formulations
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EP1895991A4 (en) Modified release formulations of anti-irritability drugs
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
GB0614586D0 (en) Pharmaceutical Formulation
IL194366A0 (en) Solid dosage formulations
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
ZA200801592B (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
EP2468771A4 (en) Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
EP2322505A4 (en) 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
HK1123998A1 (en) Pharmaceutical preparation containing garcinia acid and use thereof
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions
IL213711A (en) Pharmaceutical formulation of nanonised fenofibrate